TW200711660A - Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development - Google Patents

Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development

Info

Publication number
TW200711660A
TW200711660A TW095120699A TW95120699A TW200711660A TW 200711660 A TW200711660 A TW 200711660A TW 095120699 A TW095120699 A TW 095120699A TW 95120699 A TW95120699 A TW 95120699A TW 200711660 A TW200711660 A TW 200711660A
Authority
TW
Taiwan
Prior art keywords
progression
agents
monitoring
candidate
clinical
Prior art date
Application number
TW095120699A
Other languages
English (en)
Inventor
Marc K Hellerstein
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of TW200711660A publication Critical patent/TW200711660A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW095120699A 2005-06-10 2006-06-09 Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development TW200711660A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68961205P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
TW200711660A true TW200711660A (en) 2007-04-01

Family

ID=37532890

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095120699A TW200711660A (en) 2005-06-10 2006-06-09 Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development

Country Status (8)

Country Link
US (1) US8741589B2 (zh)
EP (1) EP1907018B1 (zh)
JP (1) JP2008543787A (zh)
AU (1) AU2006257821A1 (zh)
CA (1) CA2611033A1 (zh)
IL (1) IL187859A0 (zh)
TW (1) TW200711660A (zh)
WO (1) WO2006135879A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655298A (zh) * 2017-11-21 2020-09-11 索尔维克斯有限公司 包含氘代3-o-甲基葡萄糖用于肿瘤疾病磁共振的诊断制剂以及使用所述制剂的诊断方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910403A (en) * 1997-05-15 1999-06-08 The Regents Of University Of California Methods for measuring cellular proliferation and destruction rates in vitro and in vivo
ATE502578T1 (de) * 2001-10-24 2011-04-15 Univ California Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
WO2003068919A2 (en) 2002-02-12 2003-08-21 The Regents Of The University Of California Non-invasive method for measuring rates of biosynthesis of biological molecules by label incorporation
CA2494715C (en) 2002-07-30 2014-07-08 The Regents Of The University Of California Method for automated, large-scale measurement of the molecular flux rates using mass spectrometry
DE20211783U1 (de) * 2002-07-31 2002-11-07 Fa. Hermann Heye i.Ins., 31683 Obernkirchen Pressstempelmechanismus einer Glasformmaschine
US20060105339A1 (en) * 2002-09-04 2006-05-18 Marc Hellerstein Methods for measuring the rates of replication and death of microbial infectious agents in an infected
SG149699A1 (en) 2002-09-13 2009-02-27 Univ California Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
US20070248540A1 (en) * 2002-09-16 2007-10-25 The Regents Of The University Of California Biochemical methods for measuring metabolic fitness of tissues or whole organisms
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
US7262020B2 (en) * 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
US20050202406A1 (en) * 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
EP1723252A4 (en) * 2004-03-11 2009-07-29 Univ California TIMELY AND SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS THROUGH ISOTOPEN FINGERPRINTING UNDER CONDITIONS OF IMPROPER ISOTOPE GRADIENTS
WO2005094327A2 (en) * 2004-03-29 2005-10-13 The Regents Of The University Of California Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
JP4118918B2 (ja) * 2005-02-28 2008-07-16 シャープ株式会社 信号品質評価装置、情報記録再生装置、信号品質評価方法、記録条件決定方法、信号品質評価プログラム、信号品質評価プログラムを記録したコンピュータ読み取り可能な記録媒体
US20060251576A1 (en) * 2005-05-03 2006-11-09 The Regents Of The University Of California Methods for measuring cholesterol metabolism and transport
TW200711660A (en) 2005-06-10 2007-04-01 Univ California Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
US10646594B2 (en) * 2009-06-19 2020-05-12 Case Western Reserve University Deuterated metabolic water precursor for detecting and treating diseased tissue
WO2012147978A1 (ja) * 2011-04-28 2012-11-01 株式会社アウレオサイエンス 安定同位体２Ｈおよび／または安定同位体１３Ｃで標識されたβ－１，３－１，６グルカン、これを用いたプローブ、ならびにその製造方法
JP2014526685A (ja) 2011-09-08 2014-10-06 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 代謝流量測定、画像化、および顕微鏡法
CA2858368A1 (en) 2011-12-07 2013-06-13 Glaxosmithkline Llc Methods for determining total body skeletal muscle mass
US20130224771A1 (en) * 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
CA2882528A1 (en) * 2012-08-20 2014-02-27 Otsuka Pharmaceutical Co., Ltd. Method for measuring carbohydrate metabolism ability, and composition for use in said method
KR20210014204A (ko) 2013-03-15 2021-02-08 오츠카 세이야쿠 가부시키가이샤 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물
US9134319B2 (en) 2013-03-15 2015-09-15 The Regents Of The University Of California Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
RU2613272C1 (ru) * 2015-10-07 2017-03-15 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения Российской Федерации Способ определения компенсации сахарного диабета 1 типа у подростков
CN108827750B (zh) * 2018-07-27 2020-10-09 西北核技术研究所 一种同位素稀释定量检测方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065552A (en) 1975-05-05 1977-12-27 Giovanni Giacomo Costa Method of detecting malignant neoplasms
US4332784A (en) 1979-02-06 1982-06-01 The Radiochemical Centre Limited Dual isotope assays
SU968036A1 (ru) 1980-03-10 1982-10-23 Научно-исследовательский институт медицинской радиологии АМН СССР Способ получени меченого белка
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
EP0248924B1 (en) 1986-06-09 1989-11-23 Bruker Analytische Messtechnik GmbH Method for determining the turnover of organic material in living tissue and nmr spectrometer for performing this method
US4940658A (en) 1986-11-20 1990-07-10 University Patents, Inc. Assay for sulfhydryl amino acids and methods for detecting and distinguishing cobalamin and folic acid deficency
AU1966188A (en) 1987-08-07 1989-03-09 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
US5042488A (en) 1987-09-29 1991-08-27 The Washington University Methods employing deuterium for obtaining direct, observable deuterium magnetic resonance images in vivo and in situ
US6004781A (en) 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
GB2229718B (en) 1989-03-22 1993-01-06 Inst Molekularnoi Genetik Method for preparing hydrogen-isotape labelled biologically active organic compounds
US5217903A (en) 1990-05-15 1993-06-08 Trustees Of Boston University Measuring connective tissue breakdown products in body fluids
US5209919A (en) 1990-07-13 1993-05-11 Regents Of The University Of California Method of measurement in biological systems
CA2027714C (en) 1990-07-13 2003-01-28 Kenneth W. Turtletaub Method of measurement in biological systems
US5597548A (en) 1990-07-18 1997-01-28 Board Of Regents, The University Of Texas System 13 C Isotopomer analyses in intact tissue using (13 C) homonuclear decoupling
HU208084B (en) 1991-10-31 1993-08-30 Hyd Kutato Fejlesztoe Kft Process for producing compositions suitable for curing tumorous diseases
US5394236A (en) 1992-02-03 1995-02-28 Rutgers, The State University Methods and apparatus for isotopic analysis
US5338686A (en) 1992-04-29 1994-08-16 Hellerstein Marc K Method for measuring in vivo synthesis of biopolymers
JP2960832B2 (ja) 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5432058A (en) 1992-09-30 1995-07-11 Lange, Iii; Louis G. Method for measuring human cholesterol absorption using metabolically stable isotopes
US5506147A (en) 1993-04-15 1996-04-09 Kolhouse; J. Fred Non-invasive evaluation of maldigestion and malaborption
JP3152933B2 (ja) 1993-05-17 2001-04-03 アマーシャム・インターナショナル・ピーエルシー 細胞生化学プロセスを測定するための装置および方法
US5439803A (en) 1993-08-13 1995-08-08 The Regents Of The University Of Michigan Isotope and assay for glycolysis and the pentose phosphate pathway
DE69629097T2 (de) 1995-08-08 2004-03-18 Otsuka Pharmaceutical Co., Ltd. Diagnostische zusammensetzungen und deren anwendung in der diagnose von zentralnervösen anomalien
US5922554A (en) 1995-10-30 1999-07-13 The Regents Of The University Of California Inhibition of cellular uptake of cholesterol
DE69716838T2 (de) 1996-08-27 2003-04-10 Tokyo Gas Co. Ltd., Tokio/Tokyo Diagnostisches Mittel für Diabetes
EP0979306A4 (en) 1997-02-14 2004-09-01 Univ George Washington ASSAY FOR THE MEASUREMENT OF DNA SYNTHESIS RATES
CA2283177A1 (en) 1997-03-14 1998-09-24 Fred P. Abramson A device for continuous isotope ratio monitoring following fluorine based chemical reactions
US5910403A (en) 1997-05-15 1999-06-08 The Regents Of University Of California Methods for measuring cellular proliferation and destruction rates in vitro and in vivo
US5961470A (en) 1997-07-09 1999-10-05 Wagner; David A. Breath test for assessing hepatic function
US6329208B1 (en) 1997-07-16 2001-12-11 Board Of Regents, The University Of Texas System Methods for determining gluconeogenesis, anapleurosis and pyruvate recycling
CA2249173C (en) 1997-10-06 2008-12-16 Tokyo Gas Co., Ltd. Diagnostic agent for liver function
US5924995A (en) 1997-11-10 1999-07-20 Meretek Diagnostics Non-invasive method for the functional assessment of infants and children with an inherited metabolic disorder
US6461870B2 (en) 1998-05-06 2002-10-08 Isotechnika Inc. 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
WO1999056790A2 (en) 1998-05-06 1999-11-11 Isotechnika, Inc. 13c glucose breath test for the diagnosis of diabetes
US6284219B1 (en) 1998-06-30 2001-09-04 Phenome Sciences Inc. In vivo determination of metabolic function for use in therapy management
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
WO2000011208A1 (en) 1998-08-25 2000-03-02 University Of Washington Rapid quantitative analysis of proteins or protein function in complex mixtures
DE19839491A1 (de) 1998-08-29 2000-03-02 Hermann Heumann Verfahren zur Markierung von Biopolymeren mit Isotopen
WO2000013025A1 (en) 1998-08-31 2000-03-09 University Of Washington Stable isotope metabolic labeling for analysis of biopolymers
US6693186B2 (en) 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US6764817B1 (en) 1999-04-20 2004-07-20 Target Discovery, Inc. Methods for conducting metabolic analyses
US20030119069A1 (en) 1999-04-20 2003-06-26 Target Discovery, Inc. Labeling of protein samples
US6391649B1 (en) 1999-05-04 2002-05-21 The Rockefeller University Method for the comparative quantitative analysis of proteins and other biological material by isotopic labeling and mass spectroscopy
US7057168B2 (en) 1999-07-21 2006-06-06 Sionex Corporation Systems for differential ion mobility analysis
US6653090B1 (en) 1999-11-05 2003-11-25 University Of Alberta Methods for measuring the metabolism of and screening for drugs in isolated hearts
JP2001211782A (ja) 2000-02-02 2001-08-07 Masa Yamamoto ｔｏｂ遺伝子欠損ノックアウト非ヒト哺乳動物
ATE344456T1 (de) 2000-05-05 2006-11-15 Purdue Research Foundation Durch affinität ausgewählte unterschriftspeptide zur identifizierung und quantifizierung von proteinen
WO2001087352A1 (en) 2000-05-18 2001-11-22 Metabolic Solutions, Inc. Reverse isotope dilution assay and lactose intolerance assay
US6680203B2 (en) 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
US7048907B2 (en) 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
GB0106923D0 (en) 2001-03-20 2001-05-09 Univ Dundee Liver function test
US7256047B2 (en) 2001-05-01 2007-08-14 Board Of Regents, The University Of Texas System Measurement of gluconeogenesis and intermediary metabolism using stable isotopes
CA2451795A1 (en) 2001-06-26 2003-01-09 Paul M. Mathews Cell-based high-throughput screening methods
US6835927B2 (en) 2001-10-15 2004-12-28 Surromed, Inc. Mass spectrometric quantification of chemical mixture components
ATE502578T1 (de) 2001-10-24 2011-04-15 Univ California Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
EP1456667B2 (en) 2001-12-08 2010-01-20 Micromass UK Limited Method of mass spectrometry
US7635841B2 (en) 2001-12-12 2009-12-22 Micromass Uk Limited Method of mass spectrometry
WO2003068919A2 (en) 2002-02-12 2003-08-21 The Regents Of The University Of California Non-invasive method for measuring rates of biosynthesis of biological molecules by label incorporation
US20050281745A1 (en) 2002-03-22 2005-12-22 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Stable isotope based dynamic metabolic profiling of living organisms for characterization of metabolic diseases, drug testing and drug development
US20060100903A1 (en) 2002-03-22 2006-05-11 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Method of enhancing the efficiency of a pharmaceutical business
US20030180710A1 (en) 2002-03-22 2003-09-25 Lee Wai-Nang Paul Method of enhancing the efficiency of a pharmaceutical business
US20030180800A1 (en) * 2002-03-22 2003-09-25 Lee Wai-Nang Paul Stable isotope based dynamic metabolic profiling of living organisms for characterization of metabolic diseases, drug testing and drug development
WO2003087314A2 (en) 2002-04-05 2003-10-23 The Regents Of The University Of California Method for isolating and measuring proliferation of long-term label retaining cells and stem cells
US20030211036A1 (en) 2002-05-07 2003-11-13 Hadassa Degani Method and apparatus for monitoring and quantitatively evaluating tumor perfusion
US7510880B2 (en) 2002-06-26 2009-03-31 Gross Richard W Multidimensional mass spectrometry of serum and cellular lipids directly from biologic extracts
CA2494715C (en) 2002-07-30 2014-07-08 The Regents Of The University Of California Method for automated, large-scale measurement of the molecular flux rates using mass spectrometry
AU2003265448A1 (en) 2002-08-16 2004-03-03 The Regents Of The University Of California Dynamic hepatic recycling glucose tolerance test
US20060105339A1 (en) 2002-09-04 2006-05-18 Marc Hellerstein Methods for measuring the rates of replication and death of microbial infectious agents in an infected
SG149699A1 (en) 2002-09-13 2009-02-27 Univ California Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
EP1545628A4 (en) * 2002-09-16 2010-07-28 Univ California BIOCHEMICAL METHOD FOR MEASURING THE METABOLIC FITNESS OF WOVEN OR THE WHOLE ORGANISM
US20070248540A1 (en) 2002-09-16 2007-10-25 The Regents Of The University Of California Biochemical methods for measuring metabolic fitness of tissues or whole organisms
US7084396B2 (en) 2002-10-29 2006-08-01 Target Discovery, Inc. Method for increasing ionization efficiency in mass spectroscopy
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
US20040121305A1 (en) 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
US6906320B2 (en) 2003-04-02 2005-06-14 Merck & Co., Inc. Mass spectrometry data analysis techniques
US20050014181A1 (en) 2003-06-18 2005-01-20 Galis Zorina S. Methods and compositions for the assessment of polymer assembly
WO2005001736A2 (en) 2003-06-30 2005-01-06 Ajinomoto Co., Inc. Intracellular metabolic flux analysis method using substrate labeled with isotope
US7262020B2 (en) 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
US20050202406A1 (en) 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
US8510054B2 (en) 2004-02-05 2013-08-13 Ajinomoto Co., Inc. Intracellular metabolic flux analysis method using substrate labeled with isotope
WO2006028492A2 (en) * 2004-02-13 2006-03-16 Nuvelo, Inc. hC1Q/TNF7 AND USES THEREOF
TW200538738A (en) * 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
EP1723252A4 (en) 2004-03-11 2009-07-29 Univ California TIMELY AND SPATIAL CHARACTERIZATION OF BIOSYNTHETIC EVENTS IN LIVING ORGANISMS THROUGH ISOTOPEN FINGERPRINTING UNDER CONDITIONS OF IMPROPER ISOTOPE GRADIENTS
WO2005094327A2 (en) 2004-03-29 2005-10-13 The Regents Of The University Of California Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
WO2005098024A1 (en) 2004-03-30 2005-10-20 Kinemed, Inc. In vivo measurement of the relative fluxes through ribonucleotide reductase vs. deoxyribonucleoside pathways using isotopes
JP4654592B2 (ja) 2004-04-02 2011-03-23 味の素株式会社 代謝フラックスの決定方法
EP1824516A4 (en) 2004-10-29 2008-11-05 Target Discovery Inc GLYCAN ANALYSIS WITH DEUTERATED GLUCOSE
WO2006081521A2 (en) 2005-01-26 2006-08-03 The Regents Of The University Of Colorado Methods for diagnosis and intervention of hepatic disorders
CA2604057C (en) 2005-04-06 2014-02-11 Randall John Bateman Methods for measuring the metabolism of neurally derived biomolecules in vivo
US20060251576A1 (en) 2005-05-03 2006-11-09 The Regents Of The University Of California Methods for measuring cholesterol metabolism and transport
TW200711660A (en) 2005-06-10 2007-04-01 Univ California Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111655298A (zh) * 2017-11-21 2020-09-11 索尔维克斯有限公司 包含氘代3-o-甲基葡萄糖用于肿瘤疾病磁共振的诊断制剂以及使用所述制剂的诊断方法
CN111655298B (zh) * 2017-11-21 2023-02-03 索尔维克斯有限公司 包含氘代3-o-甲基葡萄糖用于肿瘤疾病磁共振的诊断制剂以及使用所述制剂的诊断方法

Also Published As

Publication number Publication date
US8741589B2 (en) 2014-06-03
EP1907018A4 (en) 2011-04-20
CA2611033A1 (en) 2006-12-21
JP2008543787A (ja) 2008-12-04
EP1907018A2 (en) 2008-04-09
IL187859A0 (en) 2008-03-20
EP1907018B1 (en) 2014-04-02
WO2006135879A2 (en) 2006-12-21
AU2006257821A1 (en) 2006-12-21
US20060280682A1 (en) 2006-12-14
WO2006135879A3 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
TW200711660A (en) Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
Simon et al. Quantifying disease progression in amyotrophic lateral sclerosis
Chen et al. Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density
Postuma et al. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Campbell et al. Effects of an omnivorous diet compared with a lactoovovegetarian diet on resistance-training-induced changes in body composition and skeletal muscle in older men
Tesfaye et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments
Schultz et al. Cardiorespiratory fitness attenuates the influence of amyloid on cognition
Truman et al. The armadillo as a model for peripheral neuropathy in leprosy
KR20220100851A (ko) 파킨슨병을 평가하기 위한 뉴로멜라닌 민감성 mri
Roque et al. Optic nerve ultrasound for the detection of elevated intracranial pressure in the hypertensive patient
Kogawa et al. Salivary function impairment in type 2 Diabetes patients associated with concentration and genetic polymorphisms of chromogranin A
Kim et al. Impaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus
Chung et al. Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus
Loehr et al. Eliminating Nox2 reactive oxygen species production protects dystrophic skeletal muscle from pathological calcium influx assessed in vivo by manganese‐enhanced magnetic resonance imaging
Hartman et al. Sedentary behaviors and biomarkers among breast cancer survivors
Inal et al. Prognostic value of indocyanine green elimination assessed with LiMON in septic patients
Yılmazbaş et al. The relationship between body fat ratio and blood pressure in school-age children
Derosa et al. Female Sexual Dysfunction in Subjects with Type 2 Diabetes Mellitus
Rasmussen et al. Neuropathy in adolescents with type 1 diabetes: Confirmatory diagnostic tests, bedside tests, and risk factors
Li et al. Assessment of sublingual microcirculation for the screening of diabetic nephropathy
Johannsen et al. Screening test for malignant hyperthermia in patients with persistent hyperCKemia: a pilot study
Ross et al. Pattern of injury in child fatalities resulting from child abuse
Trundell et al. F23 Validity, reliability, ability to detect change and meaningful within-patient change of the CUHDRS
Hannan et al. Cognitive and vascular function in older adults with and without CKD
Recasens et al. Ultrasonographic and manometric study of the tongue as biomarkers of dysphagia in patients with amyotrophic lateral sclerosis